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Letters to the Editor
Hypertrophic Cardiomyopathy
in Childhood
The Gradient Is Not the Disease.
Excessive Use of Experimental
Invasive Interventions
We read with much interest the study of Sreeram et al. (1) from
ermany and United Kingdom in which the authors used the
ovel strategy of radiofrequency ablation of the ventricular septum
o produce intramuscular scars and reduce outflow tract obstruc-
ion in young children with hypertrophic cardiomyopathy (HCM).
he study population is unique for HCM: 1) sizable for this age
roup (mean age: 10 years, with children as young as 2 years [n  2]
nd with 25% 6 years of age or younger); 2) symptoms attributed
o HCM although seemingly very modest (i.e., tiredness in 28
atients), with some being virtually asymptomatic; and 3) lacking
etailed information about preablation pharmacologic therapy and
o consideration for surgery.
Subaortic gradients historically have been the most visible
omponent of HCM, almost by reflex triggering concern, which is
ften disproportionate to hemodynamic significance (2). Notably,
he authors aggressively promoted invasive intervention to reduce
utflow obstruction in very young patients, using an experimental
echnique that will undoubtedly prove controversial. Radiofre-
uency ablation sufficient to reduce septal thickness strikes us as
ounterintuitive, a concern which is compounded by the authors’
ailure to report septal thickness before or after ablation.
Experimentation on children with HCM has been an unfortu-
ate part of the disease history (3). Therefore, we take this
pportunity to underscore the acknowledged principle that outflow
radients in HCM do not always represent a disease feature that
equires immediate action and abolition. Although left ventricular
utflow obstruction is a determinant of progressive heart failure in
CM (4), many patients of all ages tolerate gradients for long
eriods without surgical or other major interventions. Furthermore,gradient-related symptoms can be controlled pharmacologically
(5), including disopyramide, which is capable of reducing outflow
obstruction (6).
It is rarely (if ever) necessary to invasively remove gradients
prophylactically in the absence of severe symptoms, particularly in
young patients. This tenet is supported by the American College of
Cardiology (4,7), the American Heart Association (7), and the
European Society of Cardiology (4) consensus recommendations
and guidelines (2003 and 2011). Over the course of almost 10
years, these societies have agreed that invasive intervention to
remove outflow obstruction in HCM should be reserved for
patients with disabling heart failure symptoms. Tiredness, as
reported by Sreeram et al. (1), is difficult to interpret in HCM
patients of any age (and particularly in young children), may not be
the consequence of outflow obstruction, and is not an indication
for invasive intervention.
Indeed, one of the major concerns with prematurely undertak-
ing invasive gradient reduction in young HCM patients is under-
scored by the outcome data reported in this small cohort (n  32):
2 deaths (1 procedural death [age: 4 years] and 1 sudden death), 1
patient each with a permanent pacemaker for heart block, implant-
able defibrillator, or failure to experience symptom improvement;
and 2 patients with ventricular fibrillation, one of whom had mitral
valve replacement and myectomy at age 5 years. The adverse
consequence rate was 22%.
It is important to underscore that HCM is a complex disease,
and although outflow obstruction can be an important determinant
of clinical course, a subaortic gradient in a young patient should
not be regarded as if it were the disease itself, necessitating invasive
therapy without regard to the potential consequences.
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Research on Children With
Hypertrophic Cardiomyopathy
The Hypertrophic Cardiomyopathy Association is a 501c3 non-
profit organization founded in 1996 to serve the hypertrophic
cardiomyopathy (HCM) community in matters of advocacy, sup-
port, and education. The Hypertrophic Cardiomyopathy Associ-
ation monitors publications on HCM daily, and after review of the
paper by Sreeram et al. (1) from Germany and the United
Kingdom regarding the use of a novel strategy of radiofrequency
ablation in HCM children with obstruction, I was left wondering
why these children were experimented on at all.
HCM patients, particularly children, have a history of being
harmed by research and unbridled enthusiasm to use novel techniques,
unfortunately at great risk to these already compromised patients. I
remain perplexed with why the authors aggressively have promoted an
invasive intervention to reduce outflow obstruction in children with an
experimental technique when suitable therapies have been used,
tested, and proven in adults and then used safely in children.
The standard of care for patients with HCM with obstruction
(American College of Cardiology [2,3] as well as American Heart
ssociation [3] and European Society of Cardiology [2] through
their consensus recommendations and guidelines [2003 and
2011]), was abandoned in this study. In the past decade, these
societies have agreed that invasive interventions to remove outflow
obstruction in HCM should be reserved for those with drug-
refractory symptoms and not as a first-line approach. Further,
these recommendations have served patients well: complication
rates have decreased and quality of life has improved. The use of
tiredness as an inclusion criterion is highly disturbing because it is
a difficult symptom to interpret in HCM patients of any age and,
when reported by a third party (parent or caregiver), highly
imprecise and is not a recognized symptom of obstruction.
The results of this study are more disturbing than the concept
alone, reporting 2 deaths and 7 serious complications, including
ventricular fibrillation, need for permanent pacing, valve replace-
ment, implantable cardioverter-defibrillator implantation, failure
and need for second attempt, burns, and myectomy—totalling a
complication rate of more than 20%.
Although the HCM community of patients appreciates the
investigation of new approaches to therapy, research on children
with HCM must be held to the highest level of ethical and
scientific standards. In our opinion, this research fell short. We
disagree with the authors. This research does not merit further
investigation in children and should be abandoned.
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Reply
We thank Dr. Maron and the Hypertrophic Cardiomyopathy
Association for their interest in our paper (1). Both take issue with
the fact that one of the symptoms in this patient cohort was
tiredness. Symptoms have to be understood in the context of being
of such severity as to interfere with the child’s daily activity and
quality of life, and parents are often the best judge of that.
The standard of care for patients with hypertrophic cardiomy-
opathy (HCM), as set out in the most recent version of the
consensus guidelines, is curiously reticent when it comes to the
care of children with symptomatic HOCM (2). It makes no
mention of radiofrequency ablation, although this has been re-
ported (3). The only reference to invasive therapy in childhood is
the surgical series by Theodoro et al. (4) from the Mayo Clinic. In
this small series (n 25), 20% of patients had no reported symptoms.
Does this imply that surgery in these children was experimental or
unnecessary? The overall complication rate was similar to that re-
ported in our study (intra-aortic balloon pump, n 2; early AICD or
pacemaker implantation, n 3; and pericardiectomy, n 1). Should
we accept this uncritically as the gold standard?
There are few studies reporting on the efficacy of pharmacologic
therapy for symptomatic children with HOCM. Reasonable ques-
tions that may be asked are: which drug(s) and at what level of
evidence? It would be quite wrong to state as established fact that
suitable therapies have been “used, tested, and proven in adults and
then used safely in children,” when this is clearly not the case.
Symptomatic children with severe obstruction may represent
the worst end of the spectrum of HCM. One may argue that adult
patients have selected themselves out as having a better prognosis
simply by having lived longer. The absence of an alternative to
open heart surgery undoubtedly has resulted in a conservative
approach to HOCM in childhood. Maintaining the status quo is
not of benefit for symptomatic children with an incurable and
progressive disease. Most parent groups support efforts by the medical
profession to improve the quality of life of their children. The
theoretical considerations and rationale for the use of radiofrequency
ablation are described clearly in our paper. Avoiding complications is
paramount, but any new approach has an element of a learning curve;
this was minimized by the authors’ experience in catheter ablation
techniques, but lessons learned will improve outcomes further.
Measuring ventricular septal thickness is meaningless, because
this will remain unchanged regardless of whether a patient under-
goes surgery or pharmacological therapy. What is important is
